The modern therapy of systemic vasculitides: perspectives and challenges


Cite item

Full Text

Abstract

Systemic vasculitis is a heterogeneous group of inflammatory diseases, which are classified according to the diameter of the affected vessels. The treatment of systemic vasculitis is no longer empirical, because of increasing number of randomized clinical trials in this field. In recent years, there was a trend to limit the cumulative dose of glucocorticosteroids and immunosuppressive drugs, partially through biological drugs usage. However, biologic therapy is not always superior to combination of glucocorticosteroids and cytotoxic drugs. The efficacy of different biologic drugs varies in patients with different forms of systemic vasculitis, which creates the ground forpersonalized therapy of these diseases. Another serious problem is the absence of strict criteria to immunosuppressive therapy intensification, especially in vasculitis, affecting large vessels, due to the lack of reliable laboratory markers of disease activity. The article reviews modern approaches to the treatment of some types of systemic vasculitis, including ANCA-associated vasculitides, giant cell arteritis, Takayasu`s arteritis and cryoglobulinemic vasculitis.

About the authors

P I Novikov

Sechenov First Moscow State Medical University

зав. отд-нием ревматологии УКБ №3

A S Zykova

Lomonosov Moscow State University

Email: ansezy@gmail.com
аспирант каф. внутренних болезней

S V Moiseev

Sechenov First Moscow State Medical University; Lomonosov Moscow State University

проф. каф. внутренних болезней факультета фундаментальной медицины МГУ им. М.В. Ломоносова

References

  1. Jennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clinical and experimental nephrology. 2013;17(5):603-606. doi: 10.1007/s10157-013-0869-6
  2. Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-74.
  3. Мухин Н.А., Розина Т.П, Новиков П.И. и др. Узелковый полиартериит, ассоциированный с вирусом гепатита В (клинический разбор). Клиническая медицина. 2015;93(6):5-13.
  4. Игнатова Т.М., Чернова О.А., Бурневич Э.З., Милованова С.Ю. Успешное лечение HCV-криоглобулинемического васкулита тяжелого течения с помощью CD-20 моноклональных антител и противовирусных препаратов. Клиническая медицина. 2014;92(8):62-64.
  5. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases. 2009; 68(3):318-23. doi: 10.1136/ard.2008.088351
  6. Мухин Н.А., Мешков А.Д., Новиков П.И. и др. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики. Клиническая фармакология и терапия. 2015;24(3):79-85.
  7. Мухин Н.А., Смитиенко И.О., Новиков П.И., Семенкова Е.Н., Моисеев С.В. Артериит Такаясу: трудности диганостики, лечение и исходы в когортном исследовании у 128 больных. Клиническая фармакология и терапия. 2014; 23 (3): 55-61.
  8. Kotter I, Henes J, Wagner A, Loock J, Gross W. Does glucocorticosteroid - resistant large - vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clinical and experimental rheumatology. 2012; 30(1)(suppl 70):114-29.
  9. Bienvenu B, Ly K, Lambert M, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne. 2016;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015
  10. Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant - cell arteritis: results of a multicentre randomised controlled trial. Annals of the rheumatic diseases. 2014;73(12):2074-2081. doi: 10.1136/annrheumdis-2013-203586
  11. Hoffman G, Cid M, Rendt-Zagar K, et al. Infliximab for maintenance of glucocorticosteroid - induced remission of giant cell arteritis: a randomized trial. Annals of internal medicine. 2007;146(9):621-630.
  12. Martínez-Taboada V, Rodríguez-Valverde V, Carreño L, et al. A double - blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the rheumatic diseases. 2008;67(5):625-630.
  13. Loricera J, Blanco R, Hernández J, et al. Tocilizumab in giant cell arteritis: Multicenter open - label study of 22 patients. Seminars in arthritis and rheumatism. 2015; 44(6):717- 723. doi: 10.1016/j.semarthrit. 2014.12.005
  14. Régent A, Redeker S, Deroux A, et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. The Journal of rheumatology. 2016;43(8):1547-1552. doi: 10.3899/jrheum.151252
  15. Villiger P, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double - blind, placebo - controlled trial. The Lancet. 387(10031):1921-1927. doi: 10.1016/S0140-6736(16)00560- 2
  16. Сатыбалдыев А.М., Сатыбалдыева М.А., Насонов Е.Л. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клиническая фармакология и терапия. 2017;26(1):47-53.
  17. Stone J, Tuckwell K, Dimonaco S, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arteritis-primary-and-secondary-outcomes-from-a-phase-3-randomized-double-blind-placebo-controlled-trial/. Accessed March 27, 2017.
  18. Conway R, O'Neill L, O'Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Annals of the rheumatic diseases. 2016; 75(8):1578-1579. doi: 10.1136/annrheumdis-2016-209351
  19. Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double - blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis. Arthritis & Rheumatology. [Epub ahead of print] doi: 10.1002/art.40044
  20. Novikov P, Meshkov A, Moiseev S. Positron emission tomography in giant cell arteritis: a new diagnostic tool? Annals of the Rheumatic Disease. 2014;73(11):e70. doi: 10.1136/annrheumdis-2014-206227
  21. Hoffman G, Merkel P, Brasington R, Lenschow D, Liang P. Anti - tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis and rheumatism. 2004;50(7): 2296-2304. doi: 10.1002/art.20300
  22. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity reviews/ 2012; 11(9):678-684. doi: 10.1016/j.autrev. 2011. 11.025
  23. Новиков П.И., Смитиенко И.О., Моисеев С.В. Эффективность продолжительного лечения ингибиторами фактора некроза опухоли - α при артериите Такаясу, рефрактерном к стандартной иммуносупрессивной терапии. Клиническая фармакология и терапия. 2013;22(2):44-48.
  24. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clinical rheumatology. 2013;32(12):1827-1832. doi: 10.1007/s10067-013-2380-6
  25. Loricera J, Blanco R, Hernandez J, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clinical and Experimental Rheumatology. 2016; 34(3) (suppl 97):44-53.
  26. Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford, England). 2006; 45(5):545-548. doi: 10.1093/rheumatology/ kei266
  27. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti - interleukin-6 receptor antibody. Arthritis and rheumatism. 2008;58(4):1197-1200. doi: 10.1002/art.23373
  28. Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/circulationaha.114.014321
  29. Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double - blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis & Rheumatology. 2017 [epub ahead of print]. doi: 10.1002/art.4003
  30. O’Connor T, Carpenter H, Bidari S, Waters M, Hedna V. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology. 2014; 14:62. doi: 10.1186/1471-2377-14-62
  31. Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
  32. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford). 2016; 55(7):1159-71. doi: 10.1093/rheumatology/kev366
  33. Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology. 2016;2(2):213-224. doi: 10.1007/s40674-016- 0048-5
  34. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clinical and experimental rheumatology. 1991; 9(6):621-624.
  35. Милованова C.Ю., Козловская Л.В., Гордовская Н.Б. Полиморфизм клинических проявлений риоглобулинемического васкулита, ассоциированного с хроническим гепатитом С. Альманах клинической медицины. 2014; 30:46-51. doi: 10.18786/2072- 0505-2014-30-46-51
  36. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Annals of the rheumatic diseases. 2014; 73(9):e58. doi: 10.1136/annrheumdis-2014-205997.
  37. Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus - associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016;75(10):1777-1782. doi: 10.1136/annrheumdis-2015-208339
  38. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia M, Zignego A. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clinical and experimental rheumatology. 2003; 21(6)(suppl 32):78-84.
  39. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and rheumatism. 2012; 64(3):843-853. doi: 10.1002/art. 34331
  40. Saadoun D, Resche Rigon M, Pol S, et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus - associated mixed cryoglobulinemia vasculitis. Journal of hepatology. 2015; 62(1):24-30. doi: 10.1016/j.jhep.2014.08.015
  41. Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus - associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016; 75(10): 1777-82. doi: 10.1136/annrheumdis-2015-208339
  42. Bonacci M, Lens S, Londoño M, et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology. 2017;15(4):575-583. doi: 10.1016/j.cgh.2016.09.158
  43. Landau D, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus - associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis & Rheumatism. 2008; 58(2):604-611. doi: 10.1002/art.23305
  44. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy. Hepatology. 2016; [epub ahead of print]. doi: 10.1002/hep.28981
  45. Moiseev S, Novikov P, Mukhin N. HCV-associated cryoglobulinemia vasculitis: are its days numbered? Annals of the rheumatic diseases.2017;76(3):5. doi: 10.1136/annrheumdis-2016-210636
  46. Novikov P, Smitienko I, Bulanov N, Zykova A, Moiseev S. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Annals of the rheumatic diseases. 2016; (epub ahead of print). doi: 10.1136/annrheumdis-2016-210890
  47. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen - specific immunoassays. Annals of the rheumatic diseases. 2016; 76(4):647-653. doi: 10.1136/annrheumdis-2016-209507
  48. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the rheumatic diseases. 2008;67(7):1004-1010. doi: 10.1136/ard.2007.071936
  49. Flossmann O, Berden A, de Groot K, et al. Long - term patient survival in ANCA- associated vasculitis. Annals of the rheumatic diseases. 2011; 70(3):488-494. doi: 10.1136/ard.2010.137778
  50. Novikov P, Moiseev S, Kuznetsova E, Semenkova E, Mukhin N. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatology International. 2015; 35(5):891-898. doi:10.1007/ s00296-014-3154-4
  51. Hoffman G, Kerr G, Leavitt R, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of internal medicine. 1992;116(6): 488-498. doi: 10.7326/0003-4819- 116-6-488
  52. Faurschou M, Sorensen I, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. The Journal of rheumatology. 2008; 35(1):100-105.
  53. de Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody - associated vasculitis: a randomized trial. Annals of internal medicine. 2009; 150(10):670-680. doi: 10.7326/0003-4819-150-10-200905190-00004
  54. Harper L, Morgan M, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long - term follow - up. Annals of the rheumatic diseases. 2012; 71(6):955-960. doi: 10.1136/annrheumdis-2011-200477
  55. Jayne D, Rasmussen N, Andrassy K, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine. 2003; 349(1):36-44. doi: 10.1056/NEJMoa020286
  56. Stone J, Merkel P.A, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. The New England journal of medicine. 2010; 363(3):221-232. doi: 10.1056/NEJMoa0909905
  57. Jones R, Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. The New England journal of medicine. 2010; 363(3):211-220. doi: 10.1056/NEJMoa 0909169
  58. Yates M, Watts R, Bajema I, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the rheumatic diseases. 2016;75(9):1583-1594. doi: 10.1136/annrheumdis-2016-209133
  59. Новиков П.И., Зыкова А.С., Смитиенко И.О., Моисеев С.В. Лечение АНЦА- ассоциированных васкулитов: рекомендации EULARERA-EDTA 2016 года. Клиническая фармакология и терапия. 2017;26(1):80-87.
  60. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. The New England Journal of Medicine. 2014;371(19):1771-1780. doi: 10.1056/NEJMoa1404231
  61. Бекетова Т.В., Александрова Е.Н, Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно - практическая ревматология. 2014;52(2):147-158. doi: 10.14412/1995-4484-2014-147-158
  62. Ананьева Л.П., Соловьев С.К., Бекетова Т.В. и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно - практическая ревматология. 2014;52(5):495-506. doi: 10.14412/1995-4484-2014-495-506
  63. Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short - term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
  64. Walsh M, Merkel P, Peh C, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti - neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:3. doi: 10.1186/1745-6215- 14-73
  65. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug design, development and therapy. 2015; 9: 333-347. doi: 10.2147/DDDT.S67264
  66. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annual review of immunology. 2003; 21:231-264. doi: 10.1146/annurev.immunol.21.120601.141152
  67. Schiemann B, Gommerman J, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (New York, NY). 2001;293(5537):2111-2114. doi: 10.1126/science.1061964
  68. Bamberg C, Mackay C, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. The Journal of biological chemistry. 2010; 285(10):7633-7644. doi: 10.1074/jbc. M109.092106
  69. Jayne D, Bruchfeld A, Harper L, et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrology Dialysis Transplantation. 2016; 31(suppl 1):45. doi: 10.1093/ndt/gfw137.01
  70. Merkel P.A, Niles J, Jimenez R, et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis and Rheumatology. 2016; 68 (suppl 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally- administered-c5ar-inhibitor-for-treatment-of-patients-with-anca-associated- vasculitis/.Accessed March 27, 2017.
  71. Novikov P, Moiseev S, Bulanov N, Shchegoleva E. Bortezomib in refractory ANCA- associated vasculitis: a new option? Annals of the rheumatic diseases. 2016;75(1):9. doi: 10.1136/annrheumdis-2015-207947
  72. Тареев Е.М., Семенкова Е.Н. Астматический вариант узелкового периартериита. Клиническая медицина. 1969;7:28-34.
  73. Семенкова Е.Н. Системные васкулиты. Москва: Медицина, 1988.
  74. Загвоздкина Е.С., Новиков П.И., Моисеев С.В. Особенности клинических проявлений и течения эозинофильного гранулематоза с полиангиитом в зависимости от наличия антител к цитоплазме нейтрофилов. Клиническая фармакология и терапия. 2017;26(1):24-30.
  75. Sinico R, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis and Rheumatism. 2005;52(9):2926-2935. doi: 10.1002/art.21250
  76. Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg- Strauss). Autoimmunity Reviews. 2017;16(1):1-9. doi: 10.1016/j.autrev.2016.09.018
  77. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA). Consensus Task Force recommendations for evaluation and management. European journal of internal medicine. 2015; 26(7):545-553. doi: 10.1016/j.ejim. 2015.04. 022
  78. Puéchal X, Pagnoux C, Baron G, et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor - prognosis factors? A multicenter, double - blind randomized controlled trial. Annals of the rheumatic diseases. 2016; 75(suppl 2):77. doi: 10.1136/annrheumdis-2016-eular.6204
  79. Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Annals of the rheumatic diseases. 2014;73(3)e.12. doi: 10.1136/annrheumdis-2013-204809
  80. Mohammad A, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Annals of the Rheumatic Diseases. 2016;75:396-401. doi: 10.1136/annrheumdis-2014-206095
  81. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine. 2016;83(1):81-84. doi: 10.1016/j.jbspin.2015.04.016
  82. Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis & Rheumatology. 2016; [Epub ahead of print] doi: 10.1002/art.40015
  83. Jachiet M, Samson M, Cottin V, et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis & rheumatology (Hoboken, NJ). 2016; 68(9): 2274- 2282. doi: 10.1002/art.39663

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies